Heart failure & cardiomyopathies
Development and Validation of a Protein Risk Score for Mortality in Heart Failure : A Community Cohort Study
Authors' conclusion
Validation of the protein risk score demonstrated good calibration and evidence of predicted benefits to stratify the risk for death in HF superior to that of clinical methods.
Study context
- Population
- Patients with heart failure (HF) enrolled 2003–2012 in Southeast Minnesota, followed through 2021development 855, validation 496
- Participants
- 1,351 patients
- Comparison
- Protein risk score vs clinical model
- Outcome
- Mortality (prediction of 5-year mortality risk)
- Follow-up
- 5 years
Methodological detailscommunity-based cohort, temporal validation, Development cohort enrolled 2003–2007 (n = 855; median age 78 years; 50% women; 29% EF <40%); validation cohort 2008–2012 (n = 496; median age 76 years; 45% women; 33% EF <40%)
- Community-based cohort
- Temporal validation
- Development cohort enrolled 2003–2007 (n = 855; median age 78 years; 50% women; 29% EF <40%); validation cohort 2008–2012 (n = 496; median age 76 years; 45% women; 33% EF <40%)
Performance
As reported in the abstract
Prediction of 5-year mortality
- Proteins selected for the score (development cohort)
- 38
Original publication
Development and Validation of a Protein Risk Score for Mortality in Heart Failure : A Community Cohort Study. Ann Intern Med. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →